Nektar Therapeutics (NKTR) Receivables - Net (2010 - 2025)

Nektar Therapeutics (NKTR) posted quarterly Receivables - Net of $400000.0 for Q4 2025, up 100.0% quarter-over-quarter from $200000.0 in Q3 2025.

Nektar Therapeutics (NKTR) Receivables - Net (2010 - 2025) Analysis & Trends

Nektar Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $400000.0 for Q4 2025.

In Q4 2025, Receivables - Net changed N/A year-over-year to $400000.0; the TTM figure through Dec 2025 stood at $400000.0 (changed N/A YoY), while the FY2025 annual figure was $400000.0, changed N/A from the prior year.
Receivables - Net for Q4 2025 stood at $400000.0, up from $200000.0 in the prior quarter.
The five-year high for Receivables - Net was $30.2 million in Q1 2022, with the low at $200000.0 in Q3 2025.
The 5-year median for Receivables - Net is $4.8 million (2022), against an average of $11.3 million.
The sharpest annual moves came in 2023 and 2024: Receivables - Net slumped 90.09% in 2023, then advanced 20.77% in 2024.
Nektar Therapeutics' Receivables - Net stood at $22.5 million in 2021, then sank by 73.41% to $6.0 million in 2022, then plunged by 79.85% to $1.2 million in 2023, then slipped by 0.75% to $1.2 million in 2024, then sank by 66.56% to $400000.0 in 2025.
Business Quant data shows NKTR's Receivables - Net at $400000.0 in Q4 2025, $200000.0 in Q3 2025, and $1.2 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Nektar Therapeutics	1.49 Bn	919.46 Mn	3.16 Mn

Download Data